PDCD1 and non-small cell lung carcinoma: Pembrolizumab, another monoclonal antibody against PD-1, has also been approved for the second-line treatment of NSCLC patients, with at least 1% PD-L1 expression, as well as for the first line treatment in cases with PD-L1 overexpression (over 50%), or in combination with chemotherapy, irrespective of the PD-L1 status [4].